Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
Yuqin SongKe-Shu ZhouDehui ZouDengju LiJian-da HuHaiyan YangHuilai ZhangJie JiWei XuJie JinFangfang LvRu FengSujun GaoDao-Bin ZhouConstantine S TamDavid SimpsonMichael L WangTycel J PhillipsStephen Samuel OpatCheng FangShaohui SunJun ZhuPublished in: Cancer medicine (2023)
Zanubrutinib in second-line treatment was associated with significantly improved OS compared with later-line treatment of R/R MCL.